Navigation Links
Spending more for lung cancer treatment did not substantially increase patients' lives
Date:10/21/2007

A new study finds that survival for elderly patients with lung cancer has changed little despite large increases in healthcare expenditures for lung cancer treatment. The study by Harvard University, National Cancer Institute, and National Bureau of Economic Research researchers, published in the December 1, 2007 issue of CANCER, a peer-reviewed journal of the American Cancer Society, finds that average life-expectancy rose by less than one month between 1983 and 1997, while costs rose by over $20,000 per patient.

Lung cancer remains the top cause of cancer death in the United States, with an estimated 160,390 deaths expected to occur in 2007.

The U.S. spends more than five billion dollars a year on detection, determining the disease severity, and treatment of lung cancer. This is a significant increase over the last few decades, mirroring similar increases in general healthcare spending over the same period. The one-year survival rate for lung cancer has increased slightly, from 37 percent in 1975-1979 to 42 percent in 2002, largely due to improvements in surgical techniques and combined therapies. However the five-year survival rate for all stages of lung cancer combined has remained relatively stable, and is currently only about 16 percent.

Dr. Rebecca Woodward and her colleagues linked and analyzed non-small cell lung cancer survival data from the National Cancer Institutes Surveillance, Epidemiology, and End Results (SEER) database and Medicare Parts A and B reimbursement data from the Continuous Medicare History Sample File (CMHSF) database. Their objective was to examine changes in treatment costs and outcomes for localized, regional and metastatic lung cancer from the early 1980s to the mid-1990s.

Cost-effectiveness, as measured by the cost of an additional year of life gained, was poor, with a high average cost of $403,142. While early stage cancer treatment was more cost-effective by conventional standards than treatments for advanced disease, the gains still were limited. When analyzed by disease severity, the cost per additional year gained for local and regional disease was $143,614 and 145,861, respectively. For metastatic cancer, the cost per additional year gained was $1,190,322.

Dr. Woodward and her co-authors conclude, The additional money spent on lung cancer treatment in the mid-1990s compared to in the early 1980s did not result in a favorable economic rate of return by conventional benchmarks.


'/>"/>

Contact: Amy Molnar
amolnar@wiley.com
John Wiley & Sons, Inc.
Source:Eurekalert

Related medicine news :

1. Risk of DVT for those spending long hours in front of computers
2. Jumping The Queue Has Left Hospital Suspending Transplantation
3. Stop spending on new treatments; allocate funds to improve the existing treatments.
4. More Spending Does Not Ensure Better Healthcare
5. Western Australian Government Spending Extra For Mental Health Services
6. Overspending in Hospitals to Lead to Cutbacks
7. Lowest Spending growth in US Medicaid
8. Variation in U.S. Healthcare Spending
9. G8 Members To Announce Plans To Increase HIV/AIDS Spending at Summit
10. Spending on Diabetes Drugs Soars in US
11. Coverage for Childrens Mental Illness Reduces Out-of-Pocket Spending
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... ... students improve their chances of acceptance to a residency in a United States ... earned degrees outside the U.S. , According to data released by the ECFMG®, ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased ... Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West Dermatology’s large network ... experience in dermatology, skin cancer , and more. She graduated from the University ...
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians and ... the rise, say researchers presenting their work at the American Orthopaedic Society ... combination of evaluating the patterns of change in concussion symptom presentation, diagnostic tools ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) is ... rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a stem ... With such a challenging diagnosis that requires immediate action, patients and caregivers ...
(Date:7/20/2017)... ... ... For individuals with extended hospital stays or who are residents of nursing ... specially designed to accommodate patients with a wide range of ailments or special needs, ... has invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features many ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... 11, 2017  The global market for liquid biopsy ... $394.1 million in 2016.  Although in early stages, the ... in particular as a result of the gradual shift ... recent introduction of a significant number of new liquid ... of tumor biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... July 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... Drug Administration (FDA) has agreed to schedule an End-of-Phase ... IIb trial of its oral insulin capsule ORMD-0801 in ... trial met primary and secondary endpoints by indicating a ...
Breaking Medicine Technology: